8-KLeadership ChangesExhibits & Filings

DEXCOM INC 8-K Report, Executive Changes (Jul 10, 2009)

Filed July 10, 2009For Securities:DXCM

Summary

DexCom, Inc. (DXCM) filed a Form 8-K on July 10, 2009, to report a significant change in its Board of Directors. Effective July 9, 2009, the company appointed Eric Topol, M.D., as a Class III director, with his term set to expire in 2011. This appointment is a key development for investors as Dr. Topol is expected to bring valuable expertise to the board, potentially including service on the Compensation Committee. Dr. Topol's appointment comes with a structured compensation package primarily in the form of stock options. This includes an initial grant upon joining and annual grants thereafter, all subject to vesting over time based on continued service. The details of these stock options, including their Black-Scholes value and vesting schedules, are important for understanding potential future dilution and executive compensation strategies. The company also issued a press release detailing this appointment, which is attached as an exhibit.

Key Highlights

  • 1Appointment of Eric Topol, M.D., as a Class III director, effective July 9, 2009.
  • 2Dr. Topol's term as director is set to expire in 2011.
  • 3It is expected that Dr. Topol will serve on the Compensation Committee of the Board.
  • 4Dr. Topol will receive standard non-employee director compensation, including stock options.
  • 5Initial stock option grant to Dr. Topol has a Black-Scholes value of $300,000, vesting over 36 months.
  • 6Annual stock option grants for Dr. Topol will have a Black-Scholes value of $125,000, vesting over 12 months.
  • 7Company issued a press release on July 9, 2009, regarding Dr. Topol's appointment.

Frequently Asked Questions

Eric Topol, M.D. is a new Class III director appointed to DexCom's Board. While his specific professional background isn't detailed in this filing, his appointment is significant as it indicates the company is bringing in new leadership or expertise to its board. The expectation that he will serve on the Compensation Committee suggests a focus on executive compensation strategy and oversight.

Dr. Topol's compensation is primarily in the form of stock options. He receives an initial grant valued at $300,000 (Black-Scholes value) that vests monthly over 36 months. Additionally, he receives an annual retainer in the form of an option grant valued at $30,000 (Black-Scholes value) and subsequent annual grants of $125,000 (Black-Scholes value) that vest over 12 months. All options have an exercise price equal to the fair market value on the grant date.

The issuance of stock options to directors, including Dr. Topol, represents potential future dilution of existing shares. Investors should monitor the vesting schedules and exercise prices to understand the potential impact on the company's share count and earnings per share over time. These grants are designed to align directors' interests with long-term shareholder value.

The company issued a press release on July 9, 2009, that provides further details about Dr. Topol's appointment. This press release is attached as Exhibit 99.01 to this Form 8-K filing.